Scott Biller Ph.D. — Chief Scientific Officer at Agios Pharmaceuticals

Dr. Scott A. Biller, Ph.D., has been the Chief Scientific Officer of Agios Pharmaceuticals, Inc. since September 2010. Dr. Biller joined Agios from Novartis Pharmaceuticals, where he served as Vice President and Head of Global Discovery Chemistry at the Novartis Institutes for BioMedical Research. He has more than twenty-five years of drug discovery and development experience. At Novartis, he was responsible for the worldwide discovery chemistry functions at NIBR, including medicinal, combinatorial and computational chemistry, as well as the research metabolism and pharmacokinetics group. Prior to joining NIBR, he served as Vice President of Pharmaceutical Candidate Optimization at the Bristol-Myers Squibb (BMS) Pharmaceutical Research Institute. His work focused on the identification of superior drug candidates through the optimization of the physicochemical, ADME and safety attributes of molecules, in parallel with efficacy, in order to increase success rates from drug candidate nomination to launch. He served as the Head of Discovery Chemistry for the BMS Pharmaceutical Research Institute's Lawrenceville site, responsible for overseeing chemistry for oncology, immunology, inflammation, pulmonary diseases and cardiovascular diseases. He served as an Executive Director of Metabolic Diseases Chemistry, with responsibility for medicinal chemistry programs in hypercholesterolemia and atherosclerosis, diabetes, obesity, osteoporosis and the endocrine dysfunction of the aging population. He contributed to robust pipelines at both BMS and Novartis, culminating in one medicine launched worldwide (Onglyza for the treatment of Type 2 diabetes) and three additional drugs reaching Phase 3 clinical development. He serves as Member of Scientific Advisory Board at Denali Therapeutics Inc. He serves as a Member of Scientific Advisory Board at Arbutus Biopharma Corporation. He has been a Member of Scientific Advisory Board at Syros Pharmaceuticals, Inc. since April 2013 and Arvinas, Inc. since February 11, 2014. He serves as a Member of Scientific Advisory Board at Envoy Therapeutics, Inc. He has over 80 scientific papers and issued patents. He completed his BS degree in Chemistry at the Massachusetts Institute of Technology in 1976 where he did his undergraduate research. Dr. Biller was awarded NIH Postdoctoral Fellowship from 1982 to 1983 in natural product synthesis at Columbia University. In 1982, he completed his Ph.D. in Organic Chemistry at the California Institute of Technology.